Marshall Wace LLP Makes New $5.45 Million Investment in Progyny, Inc. (NASDAQ:PGNY)

Marshall Wace LLP bought a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 315,769 shares of the company's stock, valued at approximately $5,447,000. Marshall Wace LLP owned 0.37% of Progyny as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of PGNY. Barclays PLC raised its stake in Progyny by 530.4% during the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after acquiring an additional 594,140 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Progyny by 67.7% during the third quarter. Tidal Investments LLC now owns 60,722 shares of the company's stock valued at $1,018,000 after purchasing an additional 24,507 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Progyny by 17.0% in the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company's stock worth $759,000 after purchasing an additional 7,003 shares during the period. GAMMA Investing LLC grew its position in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after buying an additional 1,246 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its stake in Progyny by 89.8% during the 4th quarter. Central Pacific Bank Trust Division now owns 13,250 shares of the company's stock valued at $229,000 after buying an additional 6,270 shares during the period. Institutional investors own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several recent analyst reports. Bank of America boosted their target price on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group increased their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. raised their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a report on Monday, March 31st. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Progyny presently has a consensus rating of "Hold" and a consensus price target of $23.64.

Progyny Stock Performance

Shares of NASDAQ:PGNY traded up $0.07 on Tuesday, hitting $22.82. The stock had a trading volume of 84,880 shares, compared to its average volume of 1,736,597. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 39.34, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The firm's 50 day moving average price is $21.92 and its 200-day moving average price is $19.14. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $33.84.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.